A 3D digitization system for conventional radiation therapy simulation

While the majority of patients receiving external beam radiation therapy treatment are planned by CT simulation, a significant number of them are still planned using conventional simulators for various reasons. The information‐collection process in a conventional simulation is often fragmented and done with primitive tools. For example, in many institutions body contours are still acquired using solder wires and tracing paper, a time‐consuming and error‐prone procedure. We have developed a 3D digitization system to assist the information‐acquisition process at conventional simulations. The system consists of an infrared camera assembly, a wireless digitizer probe, and Windows‐based software. The system can provide 3D coordinates of any points in space accessible by the probe with submillimeter accuracy. It can be used to capture body contours, to record the coordinates of portal points, and to take various measurements for dose calculations as well as for patient setup. The software can display all the captured data together with the planned treatment fields, providing a comprehensive geometric verification of the treatment configuration. The system can also transfer all the information to dose‐planning programs in DICOM‐RT format, providing an integrated information flow from simulation to dose planning. PACS: 87.53.Vb, 87.53.X

Simulations of phase transitions in Rb2ZnCl4

Structural relaxations, molecular-dynamics simulations, and lattice-dynamics calculations were performed to study the phase transitions in Rb2ZnCl4, using intermolecular and intramolecular potentials generated from ab initio quantum-chemistry calculations for the whole molecular ion ZnCl42-. Compared with an earlier treatment of the system by a polarizable-ion model, the present approach emphasizes the static effect of the electron covalency within the molecular ions that affects strongly both the intermolecular and intramolecular interactions. The calculations gave a close agreement with experiment on the static structures of the Pnam and the Pna21 phases and the transition temperature from the former to the latter. For the lower-temperature, monoclinic phase of Rb2ZnCl4, the detailed structure of which is unknown, our simulations predict a structure with C1c1 space-group symmetry, which doubles the Pna21 structure along both the b and c axes and thus has 48 formula units per unit cell. The lattice-dynamics calculations for the Pna21 structure clearly revealed the lattice instability responsible for the Pna21-monoclinic transition and provided a more convincing explanation of a previous Raman measurement. We have shown that the potential-energy surface in Rb2ZnCl4 pertinent to the phase transitions contains a double-well structure, very similar to that of K2SeO4, except that the double well is much deeper, causing the much more severe disordering in the Pnam structure of Rb2ZnCl4 observed experimentally

Beam range uncertainty and its clinical management in particle therapy

The full theoretical advantages of particle beams in external beam radiotherapy have not been fully exploited, in large part due to uncertainties of the beam range in the patient. For this reason, efforts are underway, either for more precise in-vivo detection of Bragg peak positions or for further reduction of beam range computation errors in treatment planning. Meanwhile, management of the range uncertainty issues with mitigation techniques based on existing technology is critical in providing safe and effective treatments in clinical practice. This paper briefly reviews the definition and causes of particle range uncertainty, the uncertainty estimates currently used in clinical practice, and the corresponding mitigation techniques. It is intended to provide references for clinical practices at new and existing particle therapy centers

Phase transitions inK2ZnCl4

It is shown that the potential-energy surface in K2ZnCl4 contains a double-well structure, very similar to some of the other A2BX4 compounds (e.g., K2SeO4, Rb2ZnCl4), except that the double well is much deeper and broader, giving rise to a highly disordered high-temperature phase as observed experimentally. A lattice-dynamics study of the Pna21 structure shows an instability with the wave vector q=0.5b*+(0.5±δ)c*, providing an explanation to the incommensurate phase transition reported recently

Uncertainties and correction methods when modeling passive scattering proton therapy treatment heads with Monte Carlo

Monte Carlo models of proton therapy treatment heads are being used to improve beam delivery systems and to calculate the radiation field for patient dose calculations. The achievable accuracy of the model depends on the exact knowledge of the treatment head geometry and time structure, the material characteristics, and the underlying physics. This work aimed at studying the uncertainties in treatment head simulations for passive scattering proton therapy. The sensitivities of spread-out Bragg peak (SOBP) dose distributions on material densities, mean ionization potentials, initial proton beam energy spread and spot size were investigated. An improved understanding of the nature of these parameters may help to improve agreement between calculated and measured SOBP dose distributions and to ensure that the range, modulation width, and uniformity are within clinical tolerance levels. Furthermore, we present a method to make small corrections to the uniformity of spread-out Bragg peaks by utilizing the time structure of the beam delivery. In addition, we re-commissioned the models of the two proton treatment heads located at our facility using the aforementioned correction methods presented in this paper

Evidence of d-phenylglycine as delivering tool for improving l-dopa absorption

<p>Abstract</p> <p>Background</p> <p><it>l</it>-Dopa has been used for Parkinson's disease management for a long time. However, its wide variety in the rate and the extent of absorption remained challenge in designing suitable therapeutic regime. We report here a design of using <it>d</it>-phenylglycine to guard <it>l</it>-dopa for better absorption in the intestine via intestinal peptide transporter I (PepT1).</p> <p>Methods</p> <p><it>d</it>-Phenylglycine was chemically attached on <it>l</it>-dopa to form <it>d</it>-phenylglycine-<it>l</it>-dopa as a dipeptide prodrug of <it>l</it>-dopa. The cross-membrane transport of this dipeptide and <it>l</it>-dopa via PepT1 was compared in brush-boarder membrane vesicle (BBMV) prepared from rat intestine. The intestinal absorption was compared by <it>in situ </it>jejunal perfusion in rats. The pharmacokinetics after i.v. and p.o. administration of both compounds were also compared in Wistar rats. The striatal dopamine released after i.v. administration of <it>d</it>-phenylglycine-<it>l</it>-dopa was collected by brain microdialysis and monitored by HPLC. Anti-Parkinsonism effect was determined by counting the rotation of 6-OHDA-treated unilateral striatal lesioned rats elicited rotation with (+)-methamphetamine (MA).</p> <p>Results</p> <p>The BBMV uptake of <it>d</it>-phenylglycine-<it>l</it>-dopa was inhibited by Gly-Pro, Gly-Phe and cephradine, the typical PepT1 substrates, but not by amino acids Phe or <it>l</it>-dopa. The cross-membrane permeability (Pm*) determined in rat jejunal perfusion of <it>d</it>-phenylglycine-<it>l</it>-dopa was higher than that of <it>l</it>-dopa (2.58 ± 0.14 vs. 0.94 ± 0.10). The oral bioavailability of <it>d</it>-phenylglycine-<it>l</it>-dopa was 31.7 times higher than that of <it>l-</it>dopa in rats. A sustained releasing profile of striatal dopamine was demonstrated after i. v. injection of <it>d</it>-phenylglycine-<it>l</it>-dopa (50 mg/kg), indicated that <it>d</it>-phenylglycine-<it>l</it>-dopa might be a prodrug of dopamine. <it>d</it>-Phenylglycine-<it>l</it>-dopa was more efficient than <it>l-</it>dopa in lowering the rotation of unilateral striatal lesioned rats (19.1 ± 1.7% vs. 9.9 ± 1.4%).</p> <p>Conclusion</p> <p>The BBMV uptake studies indicated that <it>d</it>-phenylglycine facilitated the transport of <it>l</it>-dopa through the intestinal PepT1 transporter. The higher jejunal permeability and the improved systemic bioavailability of <it>d-</it>phenylglycine-<it>l</it>-dopa in comparison to that of <it>l</it>-dopa suggested that <it>d-</it>phenylglycine is an effective delivery tool for improving the oral absorption of drugs like <it>l</it>-dopa with unsatisfactory pharmacokinetics. The gradual release of dopamine in brain striatum rendered this dipeptide as a potential dopamine sustained-releasing prodrug.</p

Raman scattering and lattice-dynamical calculations of alkali-metal sulfates

Raman-scattering measurements on single crystals of K2SO4, Rb2SO4, and Cs2SO4 have been made at both room and liquid-nitrogen temperatures. Lattice-dynamical calculations, based on a rigid-ion model using the Gordon-Kim method to calculate the short-range potentials, were performed. The influence of the alkali-metal ions on the lattice-dynamical properties of the crystals is discussed

Isotopic Fractionation of Nitrogen in Ammonia in the Troposphere of Jupiter

Laboratory measurements of the photoabsorption cross section of ^(15)NH_3 at wavelengths between 140 and 220 nm are presented for the first time. Incorporating the measured photoabsorption cross sections of ^(15)NH_3 and ^(14)NH_3 into a one-dimensional photochemical diffusive model, we find that at 400 mbar, the photolytic efficiency of ^(15)NH_3 is about 38% greater than that of ^(14)NH_3. In addition, it is known that ammonia can condense in the region between 200 and 700 mbar, and the condensation tends to deplete the abundance ratio of ^(15)NH_3 and ^(14)NH_3. By matching the observed ratio of ^(15)NH_3 and ^(14)NH_3 at 400 mbar, the combined effect of photolysis and microphysics produces the ratio of (2.42 ± 0.34) × 10^(-3) in the deep atmosphere, in excellent agreement with the Galileo spacecraft measurements. The usefulness of the isotopic composition of ammonia as a tracer of chemical and dynamical processes in the troposphere of Jupiter is discussed

Vacuum-Ultraviolet Absorption Spectra of Icy C2H4 at 13–60 K

The thermal variation of absorption spectra of icy ethene in wavelength range 105–220 nm was measured from 13 to 100 K using a synchrotron as light source. Sublimation of icy ethene began above 62 K, resulting in decreasing absorption. The absorption of icy ethene increased at wavelengths less than about 150 nm with increasing temperature from 13 to 60 K, but decreased beyond above 150 nm. According to detailed examination, the absorption spectra of icy ethene intersected at isosbestic point 147.0 nm from 13 to 17 K, whereas those varied absorption profiles crossed at another point, 150.6 nm, from 23 to 60 K. These results indicate that ethene ices might exhibit three structures within temperature range 13–60 K. This work enhances our understanding of the spectra of icy ethene at low temperatures and our knowledge of its astrochemistry and astrophysics in cold astro-environments

Integration of Chinese Herbal Medicine into Routine Care Was Related to Lower Risk of Chronic Kidney Disease in Patients with Rheumatoid Arthritis: A Population-Based Nested Case–Control Study in Taiwan

Objective Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used as the first-line agents for the symptomatic relief of rheumatoid arthritis (RA), but it may insidiously provoke the onset of renal diseases, especially chronic kidney disease (CKD). While Chinese herbal medicine (CHM) has become an increasingly popular adjunctive therapy among RA groups, there are currently no available data on the effect of CHM use towards risk of CKD. This study aimed to explore on a population-level whether CHM use decreases sequent CKD risk among them. Methods In this nested case–control study retrieved from the nationwide insurance database of Taiwan from 2000 to 2012, we looked at the association between CHM use and the likelihood of developing CKD, with a focus on usage intensity. Cases with CKD claims were defined and matched to one randomly selected control case. Conditional logistic regression was then applied to estimate odds ratio (OR) of CKD from CHM treatment measured before the index date. For each OR, we calculated a 95% confidence interval for CHM use relative to the matched control. Results This nested case–control study included 5464 patients with RA, where after matching comprised 2712 cases and 2712 controls. Among them, there were 706 and 1199 cases that ever received CHM treatment, respectively. After the adjustment, CHM use in RA individuals was related to a lower likelihood of CKD, with an adjusted OR of 0.49 (95% CI: 0.44–0.56). Additionally, a dose-dependent, reverse association was found between the cumulative duration of CHM use and risk of CKD. Conclusion Integrating CHM into conventional therapy may reduce the likelihood of developing CKD, which could be a reference in instituting novel preventive strategies to improve treatment outcomes and reduce related fatalities for RA subjects